Modeling pulmonary fibrosis with bleomycin

Current Opinion in Pulmonary Medicine

Volumn 17, Issue 5, 2011, Pages 355-361

  Mouratis, Marios A ^a   Aidinis, Vassilis ^a  

^a BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

Author keywords

Bleomycin; idiopathic pulmonary fibrosis; macrophages; phospholipids

Indexed keywords

ACETYLCYSTEINE; AM 095; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN A1; ARGINASE 1; AZITHROMYCIN; BLEOMYCIN; CALVASCULIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; MICRORNA; PHOSPHOLIPID; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSING ALVEOLITIS; HOMEOSTASIS; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROBLAST; MACROPHAGE; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; REVIEW;

ANIMALS; BLEOMYCIN; DISEASE MODELS, ANIMAL; DOGS; EPITHELIAL-MESENCHYMAL TRANSITION; HOMEOSTASIS; MICE; PHOSPHOLIPIDS; PULMONARY FIBROSIS; RABBITS; RATS;

EID: 80051718091     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328349ac2b     Document Type: Review

References (70)

1. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008;3:8.
2. Coward WR, Saini G, Jenkins G. The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2010;4:367-388.
3. Harari S, Caminati A. IPF: new insight on pathogenesis and treatment. Allergy 2010;65:537-553.
4. Hardie WD, Glasser SW, Hagood JS. Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol 2009;175:3-16.
5. Taskar V, Coultas D. Exposures and idiopathic lung disease. Semin Respir Crit Care Med 2008;29:670-679.
6. du Bois RM. Genetic factors in pulmonary fibrotic disorders. Semin Respir Crit Care Med 2006;27:581-588. (Pubitemid 46048038)
7. Selman M, Rojas M, Mora AL, Pardo A. Aging and interstitial lung diseases: unraveling an old forgotten player in the pathogenesis of lung fibrosis. Semin Respir Crit Care Med 2010;31:607-617.
8. Daniels CE, Ryu JH. Treatment of idiopathic pulmonary fibrosis. Semin Respir Crit Care Med 2006;27:668-676. (Pubitemid 46048046)
9. du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010;9:129-140.
10. Rosenthal N, Brown S. The mouse ascending: perspectives for humandisease models. Nat Cell Biol 2007;9:993-999. (Pubitemid 47338136)
11. Lown JW, Sim SK. The mechanism of the bleomycin-induced cleavage of DNA. Biochem Biophys Res Commun 1977;77:1150-1157. (Pubitemid 8237568)
12. Sebti SM, Mignano JE, Jani JP, et al. Bleomycin hydrolase: molecular cloning, sequencing, and biochemical studies reveal membership in the cysteine proteinase family. Biochemistry 1989;28:6544-6548. (Pubitemid 19208303)
13. Umezawa H, Ishizuka M, Maeda K, Takeuchi T. Studies on bleomycin. Cancer 1967;20:891-895.
14. Yagoda A, Mukherji B, Young C, et al. Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Ann Intern Med 1972;77:861-870.
15. Adamson IY, Bowden DH. The pathogenesis of bloemycin-induced pulmonary fibrosis in mice. Am J Pathol 1974;77:185-197.
16. Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006;173:769-776.
17. Mungunsukh O, Griffin AJ, Lee YH, Day RM. Bleomycin induces the extrinsic apoptotic pathway in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 2010;298:L696-L703.
18. Chung MP, Monick MM, Hamzeh NY, et al. Role of repeated lung injury and genetic background in bleomycin-induced fibrosis. Am J Respir Cell Mol Biol 2003;29(3 Pt 1):375-380. (Pubitemid 37093996)
19. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;294:L152-L160. (Pubitemid 351253350)
20. Degryse AL, Tanjore H, Xu XC, et al. Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010;299:L442-L452. This article introduces the concept of repetitive intratracheal bleomycin administration and shows that it recapitulates more accurately the chronic aspect of pulmonary fibrosis. In addition, it is shown that EMT is a major contributor to the lung fibroblast population.
21. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988;41:467-470. (Pubitemid 18098428)
22. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25:25-29. (Pubitemid 30257031)
23. Hancock A, Armstrong L, Gama R, Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 1998;18:60-65. (Pubitemid 128355347)
24. Wang L, Antonini JM, Rojanasakul Y, et al. Potential role of apoptotic macrophages in pulmonary inflammation and fibrosis. J Cell Physiol 2003;194:215-224. (Pubitemid 36043636)
25. Misson P, van den Brule S, Barbarin V, et al. Markers of macrophage differentiation in experimental silicosis. J Leukoc Biol 2004;76:926-932. (Pubitemid 39458704)
26. Liu T, Jin H, Ullenbruch M, et al. Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6. J Immunol 2004;173:3425-3431. (Pubitemid 39142053)
27. Pechkovsky DV, Prasse A, Kollert F, et al. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clin Immunol 2010;137:89-101. This article suggests an important role for M2 polarized alveolar macrophages in the pathogenesis of pulmonary fibrosis and indicates that both IL-4 and IL-10 account for human alveolar macrophage phenotype shift to M2.
28. Niese KA, Chiaramonte MG, Ellies LG, et al. The cationic amino acid transporter 2 is induced in inflammatory lung models and regulates lung fibrosis. Respir Res 2010;11:87. This work led to the identification of CAT2 as a regulator of fibrotic responses in the lung by acting on the arginase activity of macrophages.
29. Pilling D, Roife D, Wang M, et al. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol 2007;179:4035-4044.
30. Haudek SB, Trial J, Xia Y, et al. Fc receptor engagement mediates differentiation of cardiac fibroblast precursor cells. Proc Natl Acad Sci USA 2008;105:10179-10184.
31. Murray LA, Rosada R, Moreira AP, et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One 2010;5:e9683. Another set of studies employed serum amyloid P in order to study its effects in the BLM-induced IPF.
32. Murray LA, Chen Q, Kramer MS, et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by serum amyloid P. Int J Biochem Cell Biol 2011;43:154-162. This implicates macrophages as key mediators in lung fibrosis.
33. Ueno M, Maeno T, Nomura M, et al. Hypoxia-inducible factor-1{alpha} mediates TGF-{beta}-induced PAI-1 production in alveolar macrophages in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2011;300:L740-L752.
34. Nagai T, Tanaka M, Hasui K, et al. Effect of an immunotoxin to folate receptor beta on bleomycin-induced experimental pulmonary fibrosis. Clin Exp Immunol 2010;161:348-356.
35. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-1428.
36. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776-1784. (Pubitemid 38063698)
37. Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006;103:13180-13185. (Pubitemid 44338936)
38. Kim KK, Wei Y, Szekeres C, et al. Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J Clin Invest 2009;119:213-224.
39. Tanjore H, Xu XC, Polosukhin VV, et al. Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med 2009;180:657-665.
40. Strieter RM, Keeley EC, Burdick MD, Mehrad B. The role of circulating mesenchymal progenitor cells, fibrocytes, in promoting pulmonary fibrosis. Trans Am Clin Climatol Assoc 2009;120:49-59.
41. Antoniou KM, Papadaki HA, Soufla G, et al. Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in idiopathic pulmonary fibrosis (IPF). Respir Med 2010;104:1535-1542. The study highlights the importance of stem cell contribution to the fibrotic stage.
42. Song JS, Kang CM, Kang HH, et al. Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. Exp Mol Med 2010;42:465-472.
43. Aguilar S, Scotton CJ, McNulty K, et al. Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One 2009;4:e8013.
44. Bitencourt CS, Pereira PA, Ramos SG, et al. Hyaluronidase recruits mesenchymal-like cells to the lung and ameliorates fibrosis. Fibrogenesis Tissue Repair 2011;4:3.
45. Jun. DH, Garat C, West J, et al. The pathology of bleomycin induced fibrosis is associated with loss of resident lung mesenchymal stem cells which regulate effector T-cell proliferation. Stem Cells 2011;29:725-735.
46. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res 2011;157:191-199.
47. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010;207:1589-1597. First indication of the involvement of microRNAs in lung fibrosis.
48. Pandit KV, Corcoran D, Yousef H, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010;182:220-229.
49. Tager AM, LaCamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008;14:45-54.
50. Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 2008;1781:513-518.
51. Nagase T, Uozumi N, Ishii S, et al. A pivotal role of cytosolic phospholipase A (2) in bleomycin-induced pulmonary fibrosis. Nat Med 2002;8:480-484. (Pubitemid 34546750)
52. Granata F, Nardicchi V, Loffredo S, et al. Secreted phospholipases A (2): a proinflammatory connection between macrophages and mast cells in the human lung. Immunobiology 2009;214:811-821.
53. Giannattasio G, Lai Y, Granata F, et al. Expression of phospholipases A2 in primary human lung macrophages: role of cytosolic phospholipase A2-alpha in arachidonic acid release and platelet activating factor synthesis. Biochim Biophys Acta 2009;1791:92-102.
54. Patel RB, Kotha SR, Sherwani SI, et al. Pulmonary fibrosis inducer, bleomycin, causes redox-sensitive activation of phospholipase D and cytotoxicity through formation of bioactive lipid signal mediator, phosphatidic acid, in lung microvascular endothelial cells. Int J Toxicol 2011;30:69-90. For the first time, this study revealed novel mechanism of activation of phospholipase D that led to the generation of phosphatidic acid, which was capable of inducing lung endothelial cell cytotoxicity, suggesting possible bioactive lipidsignaling mechanisms of microvascular disorders encountered in IPF.
55. Manoury B, Nenan S, Leclerc O, et al. The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis. Respir Res 2005;6:11.
56. Bocchino M, Agnese S, Fagone E, et al. Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis. PLoS One 2010;5:e14003.
57. Tanaka K, Ishihara T, Azuma A, et al. Therapeutic effect of lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010;298:L348-L360.
58. Oga T, Matsuoka T, Yao C, et al. Prostaglandin F (2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta. Nat Med 2009;15:1426-1430.
59. Bauman KA, Wettlaufer SH, Okunishi K, et al. The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. J Clin Invest 2010;120:1950-1960. These studies demonstrate crosstalk between plasminogen activation and PGE2 generation in the lung and provide a mechanism for the well known antifibrotic actions of the fibrinolytic pathway.
60. Senoo T, Hattori N, Tanimoto T, et al. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax 2010;65:334-340.
61. Kono Y, Nishiuma T, Nishimura Y, et al. Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-beta1. Am J Respir Cell Mol Biol 2007;37:395-404. (Pubitemid 47502714)
62. Shea BS, Brooks SF, Fontaine BA, et al. Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. Am J Respir Cell Mol Biol 2010;43:662-673.
63. Moeller A, Ask K, Warburton D, et al. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008;40:362-382. (Pubitemid 351249887)
64. Behr J, Demedts M, Buhl R, et al. Lung function in idiopathic pulmonary fibrosis: extended analyses of the IFIGENIA trial. Respir Res 2009;10:101.
65. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008;590:400-408.
66. Azuma A. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. Expert Rev Respir Med 2010;4:301-310. The study summarizes the results of clinical studies showing inhibition of IPF disease progression in patients with mild-to-moderate impairment of pulmonary functions using pirfenidone.
67. Wuyts WA, Willems S, Vos R, et al. Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model. Exp Lung Res 2010;36:602-614.
68. Kim TH, Lee YH, Kim KH, et al. Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis. Am J Respir Crit Care Med 2010;182:633-642.
69. Swaney JS, Chapman C, Correa LD, et al. Pharmacokinetic and pharmaco-dynamic characterization of an oral lysophosphatidic acid type 1 receptorselective antagonist. J Pharmacol Exp Ther 2011;336:693-700. The study demonstrated the efficacy of this LPA (1) receptor antagonist in the murine model of BLM-induced pulmonary fibrosis, underlining its potential for treating a range of clinical diseases/disorders.
70. Swaney JS, Chapman C, Correa LD, et al. A novel, orally active LPA (1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol 2010;160:1699-1713. These findings demonstrate that this receptor antagonist may be beneficial in treating lung injury and fibrosis, as well as other diseases that are characterized by pathological inflammation, edema and fibrosis.